Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$798.84M-933%-$23.36M+73.4%-$41.42M+58.5%-$58.56M+46.4%-$77.34M+51.2%
$25.07M+4.4%$24.24M+2.6%$24.23M+5.0%$24.22M+23.1%$24.02M+58.5%
$91.82M+73.9%$71.42M+47.4%$65.65M+46.2%$59.43M+43.6%$52.8M+39.3%
-$170.98M$55.83M
$1.58M+54.5%$954K-3.9%$374K$368K$1.02M
-$20.4M+80.9%-$24.96M+72.5%-$24.96M+73.1%-$40.77M+84.2%-$106.89M+20.4%
$303.86M+1,230%$40.14M+127%$36.48M+158%$24.25M-88.8%$22.85M-93.0%
$114.39M+226%$75.24M+219%$59.11M-$4.89M-$90.6M
-$172.55M$54.87M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Mirum Pharmaceuticals, Inc. generate?
Mirum Pharmaceuticals, Inc. (MIRM) generated -$171.0M in operating cash flow over the trailing twelve months.
What is Mirum Pharmaceuticals, Inc.'s free cash flow?
After $1.6M of capital expenditures, Mirum Pharmaceuticals, Inc.'s free cash flow was -$172.6M over the trailing twelve months, down 45270.7% year over year.
Where does Mirum Pharmaceuticals, Inc.'s cash flow data come from?
Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.